- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Bamlanivimab/ Etesevimab
Intervention: Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Primary care
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Adults (18-64 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Community
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- General population
- Hospital
- Intensive care unit
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Influenza
- Avian Influenza
- Pharmacological intervention
- Immunomodulator
- Baricitinib
- Statins
- Simvastatin
- Adults (18-64 years)
- Community
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Influenza
- Avian Influenza
- Pharmacological intervention
- Nitric Oxide Nasal Spray